Fundraising Fox

Myla Lai-Goldman

Investor

Venture Partner at Hatteras Venture Partners

Burlington, Vermont

Writes $100K – $5M checks Β· typically $1.5M

About

Myla Lai-Goldman is Chair and Co-Founder of GeneCentric Therapeutics, Inc. and serves as a Board Member at Mercy BioAnalytics, Inc. She spent over 18 years at LabCorp, including 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer, where she oversaw three genomic laboratories and led the introduction of more than 400 clinical assays. She holds a BS from the University of Pennsylvania and an MD from Columbia University College of Physicians and Surgeons, and is board-certified in anatomic and clinical pathology.

Experience

  1. Mercy BioAnalytics, Inc.Board Membercurrent2023 β€” present
  2. NovoPathBoard Membercurrent2022 β€” present
  3. GeneCentric Therapeutics, Inc.Co-Founder and Chaircurrent2021 β€” present
  4. GeneCentric Therapeutics, Inc.Executive Chair2019 β€” 2021Research Triangle Park, NC
  5. GeneCentric Therapeutics, Inc.Chief Executive Officer2011 β€” 2018280 S. Mangum Street Suite 350 Durham, NC 27701
  6. West Pharmaceutical ServicesBoard Membercurrent2014 β€” present
  7. Hatteras Venture PartnersVenture Partnercurrent2011 β€” present280 S Mangum St, Suite 350 Durham, NC 27701
  8. Personalized Science, LLCManaging Partnercurrent2009 β€” presentS Burlington, Vermont
  9. QuanterixBoard Member2025 β€” 2026
  10. Hitachi High-Tech America, Inc.Scientific Advisory Board Member2023 β€” 2026
  11. Akoya Biosciences, Inc.Board Member2021 β€” 2025
  12. LabCorpExecutive VP, CMO & CSO1998 β€” 2008128 East Maple Avenue, Burlington, NC 27215
  13. LabCorpPathologist, VP, SVP1990 β€” 1998

Education

  1. Columbia University Vagelos College of Physicians and SurgeonsDoctor of Medicine (MD)1979 β€” 1983
  2. University of PennsylvaniaBachelor of Arts (B.A.), Biology1975 β€” 1979

Skills & more

Strategy7Diagnostics2Hardware Diagnostics31Infectious Diseases13Biotechnology46Oncology34Personalized Medicine8Genomics8Lifesciences30Cancer7Commercialization38Immunology11
+12 moreMolecular BiologyClinical DevelopmentDrug DevelopmentTechnology TransferDrug DiscoveryPharmaceutical IndustryBiopharmaceuticalsHealthcareGeneticsBiochemistryMedical DevicesClinical Trials

From Myla's professional profile.

Same school

Shared employers

Deals Β· 1

Genecentric TherapeuticsBoard seat

via Hatteras Venture Partners Β· filed Jun 2025 Β· $5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Hatteras Venture Partners